Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

Viral Hepatit Dergisi - Viral Hepatitis Journal, published by GALENOS PUBL HOUSE, is a preeminent journal dedicated to advancing the field of viral hepatitis research. With an ISSN of 1307-9441 and an E-ISSN of 2147-2939, it serves as a vital platform for the dissemination of cutting-edge studies and clinical findings related to the prevention, diagnosis, and treatment of viral hepatitis. The journal aims to foster collaboration among researchers, medical professionals, and students by providing open access to high-quality research articles and reviews. Although specific impact metrics such as H-Index are not detailed, the journal is well-regarded in its field, contributing significantly to the understanding of viral hepatitis and its global implications. Positioned in Istanbul, Turkey, it draws upon a rich academic tradition, ensuring comprehensive coverage of the subject. This journal is indispensable for anyone invested in the fight against viral hepatitis, enriching the scholarly literature while promoting informed practices in healthcare.

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Annals of Hepatology is an esteemed open-access journal dedicated to the dynamic field of liver research and hepatology. Published by Elsevier España since 2002, this journal has established itself as a pivotal resource for researchers and clinicians alike, boasting a remarkable impact in the medical community with its 2023 rankings placing it in the Q2 quartile for Hepatology and Q1 quartile in Medicine (Miscellaneous). With an impressive Scopus rank of #20 out of 82 in the field of Hepatology and a notable 76th percentile standing, the journal is committed to disseminating high-quality, peer-reviewed articles that advance the understanding of liver diseases and their management. The editorial scope encompasses a broad range of topics, including liver pathology, therapeutic interventions, and public health implications related to hepatic disorders. Researchers, healthcare professionals, and students interested in the latest advancements in hepatology will find Annals of Hepatology an invaluable platform for sharing and accessing knowledge, with the convenience of open access enhancing global visibility and collaboration in this critical field of medicine.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

JHEP Reports, published by ELSEVIER, stands at the forefront of scholarly communication in the fields of Gastroenterology, Hepatology, Immunology and Allergy, and Internal Medicine. As an Open Access journal since 2019, it provides a platform for the dissemination of high-quality research findings, making vital information readily accessible to a global audience. With a commendable impact characterized by a Q1 category ranking across four medical disciplines in 2023, JHEP Reports demonstrates its significance and influence, reflected in its impressive Scopus ranks—#11 in Gastroenterology and #14 in Internal Medicine, amongst others. This esteemed journal not only plays a critical role in advancing knowledge but also fosters collaboration among researchers, practitioners, and students keen on exploring innovations and breakthroughs in health sciences. At RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, JHEP Reports is committed to bridging the gap between research and application, ushering in a new era of informed and effective healthcare solutions.